§ 01 / Reference
Peptide index
209 compounds catalogued. Each entry is graded on evidence strength. Blind-purchase testing data appears as the independent assay program comes online.
209
Compounds
49
Tier 1
63
Speculative
—
Mean pass
Search
Evidence tier
Category
Showing
209 / 209
| # | Compound ▲ | Also known as | Category ↕ | Evidence ↕ | Pass % ↕ | N ↕ | Supp. ↕ | |
|---|---|---|---|---|---|---|---|---|
| 01 | 5-Amino 1MQ | Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor (not a peptide; commonly sold in peptide-market channels) | Other | SPECULATIVE | — | — | — | → |
| 02 | 5-Amino-1MQ + NADH (Blend) | Two-component blend - 5-Amino-1-methylquinolinium (5-A1MQ; selective NNMT inhibitor small molecule) + NADH (reduced nicotinamide adenine dinucleotide) | Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 03 | 9-Me-BC | β-carboline alkaloid (small molecule); proposed dopamine system upregulator | Cognitive | SPECULATIVE | — | — | — | → |
| 04 | Ac2-26 | Synthetic N-acetylated 25-residue peptide derived from Annexin A1 N-terminus | Healing, Immune | TIER 3 · Preclinical | — | — | — | → |
| 05 | ACE-031 | Recombinant human activin receptor type IIB extracellular domain — IgG1 Fc fusion protein | GH-stack | TIER 2 · Translational | — | — | — | → |
| 06 | Acetyl Hexapeptide-8 | Synthetic N-acetylated hexapeptide; INCI 'Acetyl Hexapeptide-8'; SNAP-25 mimic / SNARE-targeting cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 07 | Acetyl Tetrapeptide-11 | Synthetic acetylated tetrapeptide; INCI 'Acetyl Tetrapeptide-11'; tenascin-X / dermal density cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 08 | Acetyl Tetrapeptide-2 | Synthetic acetylated tetrapeptide; INCI 'Acetyl Tetrapeptide-2'; thymus-derived cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 09 | Acetyl Tetrapeptide-5 | Synthetic acetylated tetrapeptide; INCI 'Acetyl Tetrapeptide-5'; periorbital edema / under-eye cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 10 | Acetyl Tetrapeptide-9 | Synthetic acetylated tetrapeptide; INCI 'Acetyl Tetrapeptide-9'; dermal density cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 11 | ACTH 1-24 | Synthetic 24-residue N-terminal fragment of ACTH (corticotropin); MC2R agonist | Cognitive, Immune | TIER 1 · Clinical | — | — | — | → |
| 12 | Adrafinil | Pro-drug of modafinil (small molecule, hydroxyamide of modafinil) | Cognitive | TIER 2 · Translational | — | — | — | → |
| 13 | AHK-Cu | Copper-binding tripeptide; alanyl-histidyl-lysine copper complex (analog of GHK-Cu) | Cosmetic | TIER 3 · Preclinical | — | — | — | → |
| 14 | AICAR | Synthetic AMP-mimetic small molecule; AMPK activator (acadesine) | Metabolic | TIER 2 · Translational | — | — | — | → |
| 15 | Albiglutide | Recombinant GLP-1-(7-37) fusion to human serum albumin (long-acting GLP-1 receptor agonist) | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 16 | Alpha-GPC | Cholinergic precursor (small molecule, glycerylphosphorylcholine) | Cognitive | TIER 2 · Translational | — | — | — | → |
| 17 | Amylin (native) | Endogenous 37-residue islet amyloid polypeptide; co-secreted with insulin from beta-cells; CTR/RAMP-amylin receptor agonist | Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 18 | Anamorelin | Non-peptide ghrelin receptor (GHS-R1a) agonist (small molecule) | GH secretagogue, Metabolic | TIER 2 · Translational | — | — | — | → |
| 19 | ANP-28 (Atrial Natriuretic Peptide) | Endogenous 28-residue atrial natriuretic peptide; NPR-A receptor agonist | Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 20 | AOD-9604 | Modified fragment of human growth hormone amino acids 176-191 | Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 21 | ARA-290 | 11-amino-acid peptide derived from erythropoietin; innate repair receptor (IRR) agonist | Healing | TIER 2 · Translational | — | — | — | → |
| 22 | B7-33 | Modified single-chain relaxin-2 analog; biased RXFP1 receptor agonist | Healing | SPECULATIVE | — | — | — | → |
| 23 | BAM-15 | Selective mitochondrial protonophore uncoupler (small molecule) | Metabolic, Longevity | TIER 3 · Preclinical | — | — | — | → |
| 24 | BDNF (Brain-Derived Neurotrophic Factor) | Endogenous neurotrophin (TrkB receptor ligand); recombinant | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 25 | BMP-7 | Recombinant human bone morphogenetic protein (TGF-β superfamily ligand) | Healing | TIER 1 · Clinical | — | — | — | → |
| 26 | BNP-32 (B-type Natriuretic Peptide) | Endogenous 32-residue B-type natriuretic peptide; NPR-A agonist; ventricular myocyte source | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 27 | BPC-157 | Synthetic 15-amino-acid pentadecapeptide | Healing | TIER 3 · Preclinical | — | — | — | → |
| 28 | BPC-157 + TB-500 (Wolverine Blend) | Multi-component research-peptide blend | Blend, Healing | TIER 3 · Preclinical | — | — | — | → |
| 29 | Bremelanotide | Synthetic cyclic heptapeptide analog of alpha-MSH; non-selective melanocortin receptor agonist | Other | TIER 1 · Clinical | — | — | — | → |
| 30 | Bronchogen | Khavinson-tradition tetrapeptide (Ala-Glu-Asp-Leu); proposed bronchial epithelium bioregulator | Longevity, Immune | SPECULATIVE | — | — | — | → |
| 31 | Cagrilintide | Long-acting amylin analog; AMY1/2/3 receptor agonist | Metabolic | TIER 2 · Translational | — | — | — | → |
| 32 | CagriSema | Fixed-ratio coformulation: cagrilintide (amylin agonist) plus semaglutide (GLP-1 agonist) | Metabolic | TIER 2 · Translational | — | — | — | → |
| 33 | Calcitonin | 32-amino-acid peptide hormone; calcitonin receptor agonist; salmon-derived form is most clinically used | Other | TIER 1 · Clinical | — | — | — | → |
| 34 | Calcitonin (salmon) | Synthetic salmon calcitonin analog (32-residue peptide) | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 35 | Calcitonin Gene-Related Peptide (CGRP) | Endogenous 37-residue calcitonin gene-related peptide; CGRP receptor (CALCRL/RAMP1) agonist | Cognitive | TIER 1 · Clinical | — | — | — | → |
| 36 | Capromorelin | Non-peptide ghrelin receptor (GHS-R1a) agonist (spiroindoline class) | GH secretagogue | TIER 1 · Clinical | — | — | — | → |
| 37 | Cardiogen | Khavinson-tradition tripeptide (Ala-Glu-Asp); proposed cardiac muscle bioregulator | Longevity | SPECULATIVE | — | — | — | → |
| 38 | Cartalax | Khavinson-tradition tripeptide; proposed cartilage bioregulator | Longevity, Healing | SPECULATIVE | — | — | — | → |
| 39 | Cerebrolysin | Porcine-brain-derived peptide preparation (low-molecular-weight neuropeptides plus free amino acids) | Cognitive | TIER 2 · Translational | — | — | — | → |
| 40 | Chelohart | Khavinson-tradition cardiac muscle bioregulator (variant) | Longevity | SPECULATIVE | — | — | — | → |
| 41 | Chitomur | Khavinson-tradition urinary bladder muscle bioregulator (KE-class) | Longevity | SPECULATIVE | — | — | — | → |
| 42 | Cholecystokinin-33 | Endogenous 33-residue gut peptide; CCK-A and CCK-B receptor agonist; full-length form (the 8mer sincalide is the synthetic clinical analog) | Cognitive, Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 43 | Chonluten | Khavinson-tradition tripeptide (Glu-Asp-Gly); proposed chondrogenic / bronchopulmonary bioregulator | Longevity | SPECULATIVE | — | — | — | → |
| 44 | Citicoline | CDP-choline (small molecule, nucleotide-choline conjugate) | Cognitive | TIER 2 · Translational | — | — | — | → |
| 45 | CJC-1295 | Tetrasubstituted GHRH(1-29) analog; DAC variant covalently binds albumin for extended half-life | GH secretagogue | SPECULATIVE | — | — | — | → |
| 46 | CJC-1295 + Ipamorelin (Blend) | Two-component vendor blend — CJC-1295 (with or without DAC; vendors vary) plus ipamorelin (selective GHS-R1a hexapeptide) | Blend, GH-stack | SPECULATIVE | — | — | — | → |
| 47 | CJC-1295 with DAC | Modified human GHRH(1-29) analog with drug-affinity-complex (DAC) maleimide group for covalent albumin binding | GH secretagogue | SPECULATIVE | — | — | — | → |
| 48 | CJC-1295 without DAC | Tetrasubstituted human GHRH(1-29) analog (D-Ala2, Gln8, Ala15, Leu27) | GH secretagogue | SPECULATIVE | — | — | — | → |
| 49 | Coenzyme Q10 (injectable) | Coenzyme Q10 (ubiquinone); injectable research-grade preparation; mitochondrial electron transport cofactor | Longevity, Metabolic | TIER 2 · Translational | — | — | — | → |
| 50 | Cortagen | Khavinson-tradition tetrapeptide (Ala-Glu-Asp-Pro); proposed cerebral cortex bioregulator | Longevity, Cognitive | SPECULATIVE | — | — | — | → |
| 51 | Cortistatin | Endogenous somatostatin-family neuropeptide; binds somatostatin receptors SSTR1 through SSTR5 with comparable affinity to somatostatin, plus the ghrelin receptor (GHS-R1a) and (in mast cells) MrgX2 — a broader receptor profile than somatostatin | Cognitive, Immune | TIER 3 · Preclinical | — | — | — | → |
| 52 | Crystagen | Khavinson-tradition tripeptide (Glu-Asp-Pro); proposed immune bioregulator | Longevity, Immune | SPECULATIVE | — | — | — | → |
| 53 | Danuglipron | Oral small-molecule GLP-1 receptor agonist (Pfizer) | Metabolic | TIER 2 · Translational | — | — | — | → |
| 54 | Dermorphin | 7-amino-acid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) from amphibian skin; mu-opioid agonist | Other | SPECULATIVE | — | — | — | → |
| 55 | Desmopressin | Synthetic analog of vasopressin; selective V2-receptor agonist | Other | TIER 1 · Clinical | — | — | — | → |
| 56 | Dihexa | Synthetic hexapeptide; angiotensin IV analog | Cognitive | SPECULATIVE | — | — | — | → |
| 57 | Dipeptide Diaminobutyroyl Benzylamide Diacetate | Synthetic snake-venom mimetic dipeptide; Waglerin-1-derived; nicotinic acetylcholine receptor antagonist; INCI 'Dipeptide Diaminobutyroyl Benzylamide Diacetate' | Cosmetic | SPECULATIVE | — | — | — | → |
| 58 | DSIP | 9-amino-acid peptide isolated from rabbit brain in 1977 | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 59 | Dulaglutide | GLP-1 analog fused to IgG4 Fc fragment; long-acting GLP-1 receptor agonist | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 60 | Dutasteride | Dual 5-alpha-reductase inhibitor (type 1 and type 2; small molecule) | Cosmetic | TIER 1 · Clinical | — | — | — | → |
| 61 | Ecnoglutide | Biased GLP-1 receptor agonist (functional selectivity for cAMP over beta-arrestin) | Metabolic | TIER 2 · Translational | — | — | — | → |
| 62 | Efpeglenatide | Long-acting GLP-1 receptor agonist with glucagon receptor selectivity (Hanmi/Sanofi) | Metabolic | TIER 2 · Translational | — | — | — | → |
| 63 | EGF (Epidermal Growth Factor) | Recombinant human epidermal growth factor; EGFR ligand | Cosmetic, Healing | TIER 2 · Translational | — | — | — | → |
| 64 | Enclomiphene | Selective estrogen receptor modulator (SERM); trans-isomer of clomiphene citrate | Sexual / hormonal | TIER 2 · Translational | — | — | — | → |
| 65 | Endoluten | Khavinson-tradition extended pineal bioregulator (AEDG-related; epitalon analog) | Longevity | SPECULATIVE | — | — | — | → |
| 66 | Epitalon | Synthetic tetrapeptide Ala-Glu-Asp-Gly | Cognitive | SPECULATIVE | — | — | — | → |
| 67 | Exenatide | Synthetic version of exendin-4 (Gila monster saliva); GLP-1 receptor agonist | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 68 | Fasoracetam | Racetam-class nootropic (small molecule); proposed mGluR3 / Group II metabotropic glutamate receptor agonist | Cognitive | TIER 2 · Translational | — | — | — | → |
| 69 | FGF-2 (Basic Fibroblast Growth Factor) | Recombinant basic fibroblast growth factor; FGFR1c agonist (and FGFR2/3/4 binding) | Cosmetic, Healing | TIER 2 · Translational | — | — | — | → |
| 70 | FGF-21 (Fibroblast Growth Factor 21) | Endogenous fibroblast growth factor 21; beta-Klotho/FGFR1c receptor complex agonist | Metabolic, Longevity | TIER 2 · Translational | — | — | — | → |
| 71 | Finasteride | Selective 5-alpha-reductase type 2 inhibitor (small molecule) | Cosmetic | TIER 1 · Clinical | — | — | — | → |
| 72 | Follistatin + B-Complex (SlimAssist Blend) | Two-component blend — recombinant follistatin (FST-315 or FST-344, vendor-dependent) plus B-vitamin complex (composition varies) | Blend, GH-stack | SPECULATIVE | — | — | — | → |
| 73 | Follistatin-315 (FST-315) | Native follistatin short isoform (315 residues; predominant circulating form) | GH-stack | TIER 3 · Preclinical | — | — | — | → |
| 74 | Follistatin-344 (FST-344) | Native follistatin long isoform (344 residues; high heparan sulfate binding, tissue-retained) | GH-stack | TIER 3 · Preclinical | — | — | — | → |
| 75 | FOXO4-DRI | D-amino-acid retro-inverso peptide designed to interfere with FOXO4-p53 interaction | Cognitive | SPECULATIVE | — | — | — | → |
| 76 | GDNF (Glial Cell Line-Derived Neurotrophic Factor) | Endogenous neurotrophin (TGF-beta superfamily; RET receptor signalling); recombinant | Cognitive | TIER 2 · Translational | — | — | — | → |
| 77 | GHK (Glycyl-Histidyl-Lysine) | Native tripeptide glycyl-histidyl-lysine (GHL); copper-free form | Cosmetic, Healing | TIER 3 · Preclinical | — | — | — | → |
| 78 | GHK-Cu | Naturally occurring tripeptide (Gly-His-Lys) complexed with copper(II) | Healing | TIER 2 · Translational | — | — | — | → |
| 79 | Ghrelin (native) | Endogenous 28-residue peptide hormone (octanoylated at Ser3) — primary GHS-R1a ligand | GH secretagogue, Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 80 | GHRP-2 | Synthetic hexapeptide; ghrelin / GHS-R1a receptor agonist | GH secretagogue | TIER 2 · Translational | — | — | — | → |
| 81 | GHRP-6 | Synthetic hexapeptide; ghrelin / GHS-R1a receptor agonist; first characterized GHRP | GH secretagogue | SPECULATIVE | — | — | — | → |
| 82 | GHRP-7 | Synthetic hexapeptide growth-hormone-releasing peptide (GHS-R1a agonist class) | GH secretagogue | SPECULATIVE | — | — | — | → |
| 83 | Glandokort | Khavinson-tradition adrenal cortex bioregulator | Longevity | SPECULATIVE | — | — | — | → |
| 84 | GLP-2 (native) | Endogenous 33-residue intestinotrophic gut peptide; cleaved from proglucagon | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 85 | Glucagon (rescue) | Recombinant 29-residue glucagon peptide; native glucagon receptor agonist | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 86 | Glucagon-like Peptide-1 (native) | Endogenous 30- or 31-residue intestinotrophic gut peptide (GLP-1(7-36)NH2 or GLP-1(7-37)); GLP-1R agonist | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 87 | Glutathione | Tripeptide; endogenous antioxidant (not a classical peptide hormone) | Other | TIER 2 · Translational | — | — | — | → |
| 88 | Glycine (research-grade spray) | Endogenous non-essential amino acid; NMDA glycine-binding site agonist | Longevity, Cognitive | TIER 2 · Translational | — | — | — | → |
| 89 | Gonadorelin | Native human gonadotropin-releasing hormone — decapeptide | Sexual / hormonal | TIER 1 · Clinical | — | — | — | → |
| 90 | HCG (Human Chorionic Gonadotropin) | Glycoprotein heterodimer — α-subunit (common to LH, FSH, TSH) plus hCG-specific β-subunit | Sexual / hormonal | TIER 1 · Clinical | — | — | — | → |
| 91 | Hexapeptide-11 | Synthetic hexapeptide; INCI 'Hexapeptide-11'; anti-senescence cosmetic peptide | Cosmetic, Longevity | SPECULATIVE | — | — | — | → |
| 92 | Hexapeptide-40 | Synthetic hexapeptide; INCI 'Hexapeptide-40'; sirtuin-1 (SIRT1) activating cosmetic peptide | Cosmetic, Longevity | SPECULATIVE | — | — | — | → |
| 93 | Hexapeptide-44 | Synthetic hexapeptide; INCI 'Hexapeptide-44'; lamin B1 upregulating cosmetic peptide | Cosmetic, Longevity | SPECULATIVE | — | — | — | → |
| 94 | Hexarelin | Synthetic hexapeptide; potent ghrelin/GHS-R1a agonist; also CD36 ligand | GH secretagogue | TIER 3 · Preclinical | — | — | — | → |
| 95 | HGH Fragment 176-191 (AOD-9604) | Synthetic 16-residue C-terminal fragment of human growth hormone (residues 176-191); proposed lipolytic without GH-axis activation | Metabolic | TIER 2 · Translational | — | — | — | → |
| 96 | Honluten | Khavinson-tradition tripeptide (Lys-Glu-Asp); proposed lung tissue bioregulator | Longevity | SPECULATIVE | — | — | — | → |
| 97 | Humanin | 24-amino-acid mitochondrial-derived peptide encoded within the MT-RNR2 gene | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 98 | IGF-1 LR3 | Modified IGF-1 analog with N-terminal extension and Arg-for-Glu substitution at position 3; reduced IGFBP affinity | GH secretagogue | SPECULATIVE | — | — | — | → |
| 99 | Insulin and insulin analogs | Class page — recombinant human insulin and engineered analogs (rapid: lispro, aspart, glulisine; long: glargine, detemir, degludec; ultra-long: icodec) | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 100 | Ipamorelin | Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) ghrelin / GHS-R1a receptor agonist | GH secretagogue | SPECULATIVE | — | — | — | → |
| 101 | Kisspeptin-10 | 10-amino-acid C-terminal fragment of kisspeptin; KISS1R (GPR54) receptor agonist | Other | TIER 2 · Translational | — | — | — | → |
| 102 | KPV (Lys-Pro-Val) | Synthetic tripeptide — C-terminal fragment of α-MSH (residues 11-13) | Healing, Immune | TIER 3 · Preclinical | — | — | — | → |
| 103 | L-Carnitine | Endogenous quaternary ammonium small molecule; mitochondrial fatty-acid transporter cofactor | Metabolic | TIER 2 · Translational | — | — | — | → |
| 104 | Leuprolide | Synthetic GnRH (gonadotropin-releasing hormone) superagonist — nonapeptide-amide | Sexual / hormonal | TIER 1 · Clinical | — | — | — | → |
| 105 | Liquid Glutathione | Reduced glutathione (GSH); endogenous tripeptide antioxidant (gamma-Glu-Cys-Gly) | Longevity | TIER 2 · Translational | — | — | — | → |
| 106 | Liraglutide | Acylated GLP-1 receptor agonist; predecessor of semaglutide | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 107 | Livagen | Khavinson-tradition tetrapeptide (Lys-Glu-Asp-Ala); proposed liver bioregulator | Longevity | SPECULATIVE | — | — | — | → |
| 108 | Lixisenatide | Synthetic 44-residue exendin-4 analog; short-acting GLP-1 receptor agonist | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 109 | LL-37 | 37-amino-acid cationic antimicrobial peptide; human cathelicidin | Healing | TIER 3 · Preclinical | — | — | — | → |
| 110 | Maralixibat | Selective ileal bile acid transporter (IBAT/ASBT) inhibitor (small molecule) | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 111 | Matrixyl | Synthetic palmitoylated pentapeptide; INCI 'Palmitoyl Pentapeptide-4'; collagen-stimulating cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 112 | Mazdutide | Dual GLP-1 / glucagon receptor agonist (Innovent Biologics + Eli Lilly co-development) | Metabolic | TIER 2 · Translational | — | — | — | → |
| 113 | Melanotan II | Synthetic cyclic heptapeptide analog of alpha-MSH; broad melanocortin receptor agonist | Other | TIER 3 · Preclinical | — | — | — | → |
| 114 | Melanotan-1 (Afamelanotide) | Synthetic alpha-MSH analog; cyclic 13-residue peptide; MC1R-selective melanocortin agonist | Cosmetic, Sexual / hormonal | TIER 1 · Clinical | — | — | — | → |
| 115 | Metformin | Biguanide-class oral antihyperglycaemic (small molecule); complex I inhibition; AMPK activator | Longevity, Metabolic | TIER 1 · Clinical | — | — | — | → |
| 116 | Methylene Blue | Phenothiazine dye (small molecule); mitochondrial alternative electron carrier; MAO inhibitor at high doses | Longevity, Cognitive | TIER 1 · Clinical | — | — | — | → |
| 117 | MGF | Synthetic peptide — C-terminal E-domain of the IGF-1Ec splice variant | GH-stack | TIER 3 · Preclinical | — | — | — | → |
| 118 | Minoxidil | Vasodilator small molecule; ATP-sensitive potassium channel opener | Cosmetic | TIER 1 · Clinical | — | — | — | → |
| 119 | MK-677 | Non-peptide spiroindoline small molecule; oral ghrelin / GHS-R1a receptor agonist | GH secretagogue | TIER 2 · Translational | — | — | — | → |
| 120 | Modafinil | Wakefulness-promoting agent (small molecule, sulfinyl class) | Cognitive | TIER 1 · Clinical | — | — | — | → |
| 121 | Motilin | Endogenous 22-residue gut peptide; motilin receptor (MLNR/GPR38) agonist | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 122 | MOTS-c | 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene | Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 123 | Myostatin Inhibitor (research class) | Heterogeneous class — soluble receptor decoys (ACE-031), monoclonal antibodies (domagrozumab, taldefgrobep), engineered peptide ligands. Vendor product chemistry is typically unspecified. | GH-stack | TIER 3 · Preclinical | — | — | — | → |
| 124 | Myristoyl Pentapeptide-17 | Synthetic myristoylated pentapeptide; INCI 'Myristoyl Pentapeptide-17'; eyelash growth cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 125 | N-Acetyl-Selank | N-acetylated heptapeptide; Russian-origin nootropic; modified Selank for stability | Cognitive | SPECULATIVE | — | — | — | → |
| 126 | N-Acetyl-Semax-Amidate | Modified heptapeptide derivative of Semax (ACTH(4-10) analog); N-acetylated and C-amidated for stability | Cognitive | SPECULATIVE | — | — | — | → |
| 127 | NAD | Endogenous nicotinamide adenine dinucleotide; NAD+ research compound (injectable / IV) | Longevity | TIER 2 · Translational | — | — | — | → |
| 128 | Nesiritide | Recombinant 32-residue B-type natriuretic peptide (BNP-32); NPR-A receptor agonist | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 129 | Neuropeptide Y | Endogenous 36-residue hypothalamic neuropeptide; pancreatic polypeptide family; Y1-Y5 receptor agonist | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 130 | NGF (Nerve Growth Factor) | Endogenous neurotrophin (beta-subunit homodimer of NGF complex); recombinant | Cognitive | TIER 2 · Translational | — | — | — | → |
| 131 | NMN | Nicotinamide mononucleotide; NAD+ precursor (small molecule) | Longevity | TIER 2 · Translational | — | — | — | → |
| 132 | Noopept | Synthetic peptide-derived nootropic (small molecule); cleaves to bioactive cyclic prolyl-glycine in vivo | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 133 | NR | Nicotinamide riboside; NAD+ precursor (small molecule) | Longevity | TIER 2 · Translational | — | — | — | → |
| 134 | Octreotide | Synthetic cyclic octapeptide analog of somatostatin; SSTR2/SSTR5 agonist | Other | TIER 1 · Clinical | — | — | — | → |
| 135 | Orforglipron | Oral small-molecule GLP-1 receptor agonist (Eli Lilly, biased) | Metabolic | TIER 2 · Translational | — | — | — | → |
| 136 | Osteogenic Peptide (BMP-mimetic class) | Heterogeneous class — synthetic peptides typically 15-30 residues derived from BMP-2 or BMP-7 knuckle-epitope regions | Healing | TIER 3 · Preclinical | — | — | — | → |
| 137 | Ovagen | Khavinson-tradition liver/ovarian bioregulator (Glu-Asp-Leu and related) | Longevity | SPECULATIVE | — | — | — | → |
| 138 | Oxyntomodulin | Endogenous 37-residue dual GLP-1 + glucagon receptor agonist; cleavage product of proglucagon | Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 139 | Oxytocin | Nonapeptide (9 amino acids with disulfide bond); OT receptor agonist | Other | TIER 1 · Clinical | — | — | — | → |
| 140 | P-21 | Synthetic 11-residue peptide derived from a region of ciliary neurotrophic factor (CNTF); proposed neurogenic and neuroprotective agent | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 141 | Palmitoyl Hexapeptide-12 | Synthetic palmitoylated hexapeptide; INCI 'Palmitoyl Hexapeptide-12'; elastin-stimulating cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 142 | Palmitoyl Tetrapeptide-7 | Synthetic palmitoylated tetrapeptide; INCI 'Palmitoyl Tetrapeptide-7'; anti-inflammatory cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 143 | Palmitoyl Tripeptide-1 | Synthetic palmitoylated tripeptide; INCI 'Palmitoyl Tripeptide-1'; topicalised GHK (palmitoyl-glycyl-histidyl-lysine) | Cosmetic | SPECULATIVE | — | — | — | → |
| 144 | Palmitoyl Tripeptide-5 | Synthetic palmitoylated tripeptide; INCI 'Palmitoyl Tripeptide-5'; TGF-β mimetic cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 145 | Pancragen | Khavinson-tradition tetrapeptide (Lys-Glu-Asp-Trp); proposed pancreatic islet bioregulator | Longevity | SPECULATIVE | — | — | — | → |
| 146 | Pasireotide | Multireceptor somatostatin analog; cyclohexapeptide; binds SSTR1, SSTR2, SSTR3, and SSTR5 with high affinity (broader profile than octreotide which is selective for SSTR2) | Cognitive, Metabolic | TIER 1 · Clinical | — | — | — | → |
| 147 | PDA (Pentadeca-Arginate) | Arginate salt formulation of the BPC-157 pentadecapeptide sequence | Healing | TIER 3 · Preclinical | — | — | — | → |
| 148 | PDRN (Polydeoxyribonucleotide) | Polydeoxyribonucleotide; salmon-DNA fragments (50 to 1500 base pairs typical); A2A adenosine receptor agonist | Cosmetic, Healing | TIER 2 · Translational | — | — | — | → |
| 149 | PE 22-28 | 7-amino-acid fragment of B-cell-derived PEPITEM protein | Healing | SPECULATIVE | — | — | — | → |
| 150 | PEG-MGF | PEGylated synthetic peptide (MGF E-domain 24mer with PEG conjugation; PEG MW unspecified by vendors) | GH-stack | TIER 3 · Preclinical | — | — | — | → |
| 151 | Pentapeptide-3 | Synthetic pentapeptide; INCI 'Pentapeptide-3'; nicotinic acetylcholine receptor blocker (topical) | Cosmetic | SPECULATIVE | — | — | — | → |
| 152 | Peptide YY (PYY) | Endogenous 36-residue peptide YY; pancreatic polypeptide family; Y2 receptor preferred (especially PYY 3-36) | Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 153 | Phenibut | GABA-B receptor agonist (small molecule, β-aryl-GABA derivative) | Cognitive | TIER 2 · Translational | — | — | — | → |
| 154 | Pinealon | Synthetic tetrapeptide; Khavinson-tradition pineal bioregulator; sequence shared with Epitalon | Cognitive, Longevity | SPECULATIVE | — | — | — | → |
| 155 | Piracetam | Original racetam-class nootropic (small molecule, pyrrolidone derivative) | Cognitive | TIER 2 · Translational | — | — | — | → |
| 156 | PNC-27 | Synthetic 32-residue peptide combining an HDM-2 (MDM2) binding region from p53 with a membrane-residency leader; designed for tumour-selective membrane disruption | Cognitive, Other | TIER 3 · Preclinical | — | — | — | → |
| 157 | PQQ | Pyrroloquinoline quinone (small molecule, redox cofactor); proposed mitochondrial biogenesis inducer | Longevity | TIER 3 · Preclinical | — | — | — | → |
| 158 | Pramlintide | Synthetic amylin analog (37-residue, 3 amino-acid substitutions for solubility) | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 159 | Raloxifene | Selective estrogen receptor modulator (SERM); benzothiophene class | Sexual / hormonal | TIER 1 · Clinical | — | — | — | → |
| 160 | Rapamycin | Macrolide mTOR inhibitor (small molecule); endogenously produced by Streptomyces hygroscopicus | Longevity | TIER 1 · Clinical | — | — | — | → |
| 161 | Retatrutide | Triple agonist of GIP, GLP-1, and glucagon receptors | Metabolic | TIER 2 · Translational | — | — | — | → |
| 162 | Retatrutide + Cagrilintide (Blend) | Two-component blend — retatrutide (triple GLP-1/GIP/glucagon agonist) plus cagrilintide (long-acting amylin analog) | Blend, Metabolic | TIER 2 · Translational | — | — | — | → |
| 163 | Retatrutide + Tirzepatide (Blend) | Two-component blend — retatrutide (triple GLP-1/GIP/glucagon agonist) plus tirzepatide (dual GLP-1/GIP agonist) | Blend, Metabolic | TIER 2 · Translational | — | — | — | → |
| 164 | RG3 Snake Venom | Synthetic snake-venom mimetic peptide; topical cosmetic | Cosmetic | SPECULATIVE | — | — | — | → |
| 165 | Secretin | Endogenous 27-residue gut peptide; secretin receptor (SCTR) agonist; foundational discovery hormone (Bayliss & Starling 1902) | Cognitive, Metabolic | TIER 1 · Clinical | — | — | — | → |
| 166 | Selank | Synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (stabilized analog of tuftsin) | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 167 | Semaglutide | Long-acting GLP-1 receptor agonist | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 168 | Semax | Synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (stabilized ACTH(4-10) fragment analog) | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 169 | Sermorelin | Synthetic GHRH(1-29)-NH2 — minimum bioactive fragment of endogenous GHRH | GH secretagogue | TIER 1 · Clinical | — | — | — | → |
| 170 | Setmelanotide | Synthetic melanocortin-4 receptor (MC4R) selective agonist; cyclic 8-residue peptide | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 171 | Sigumir | Khavinson-tradition joint cartilage bioregulator (AED variant) | Longevity, Healing | SPECULATIVE | — | — | — | → |
| 172 | Sildenafil | Phosphodiesterase type 5 (PDE-5) inhibitor; pyrazolopyrimidinone class | Sexual / hormonal | TIER 1 · Clinical | — | — | — | → |
| 173 | Sincalide | Synthetic CCK-8 octapeptide; CCK-A and CCK-B receptor agonist | Cognitive, Metabolic | TIER 1 · Clinical | — | — | — | → |
| 174 | SLU-PP-332 | Estrogen-related receptor (ERR) agonist (small molecule) | Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 175 | SNAP-8 | Synthetic acetylated octapeptide; INCI 'Acetyl Octapeptide-3'; SNARE complex / SNAP-25 mimic | Cosmetic | SPECULATIVE | — | — | — | → |
| 176 | Somatropin | Recombinant 191-amino-acid human growth hormone | GH secretagogue | TIER 1 · Clinical | — | — | — | → |
| 177 | Spermidine | Endogenous polyamine; autophagy inducer (small molecule) | Longevity | TIER 3 · Preclinical | — | — | — | → |
| 178 | Splenopentin | Synthetic pentapeptide derived from splenin | Immune | SPECULATIVE | — | — | — | → |
| 179 | SR-9009 | REV-ERB nuclear receptor agonist (small molecule) | Metabolic | TIER 3 · Preclinical | — | — | — | → |
| 180 | SS-31 | Synthetic mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane | Cognitive | TIER 2 · Translational | — | — | — | → |
| 181 | Substance P | Endogenous undecapeptide; tachykinin family; NK1 receptor agonist | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 182 | Survodutide | Dual GLP-1 / glucagon receptor agonist (Boehringer Ingelheim + Zealand Pharma) | Metabolic | TIER 2 · Translational | — | — | — | → |
| 183 | Syn-Ake | Synthetic tripeptide; INCI 'Tripeptide-3'; beta-Ala-Pro-Dab-NHBn benzylamide; snake-venom (waglerin) mimetic | Cosmetic | SPECULATIVE | — | — | — | → |
| 184 | Tadalafil | Phosphodiesterase type 5 (PDE-5) inhibitor; β-carboline class | Sexual / hormonal | TIER 1 · Clinical | — | — | — | → |
| 185 | Tamoxifen | Selective estrogen receptor modulator (SERM); triphenylethylene class | Sexual / hormonal | TIER 1 · Clinical | — | — | — | → |
| 186 | TB-500 | Naturally occurring 43-amino-acid peptide (Tβ4); TB-500 often used commercially as a synonym though technically refers to a synthetic fragment | Healing | TIER 2 · Translational | — | — | — | → |
| 187 | Teduglutide | Recombinant analog of GLP-2; selective GLP-2 receptor agonist | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 188 | Teriparatide | Recombinant human parathyroid hormone amino acids 1-34 | Other | TIER 1 · Clinical | — | — | — | → |
| 189 | Tesamorelin | Stabilized human growth hormone-releasing hormone (1-44) analog | GH secretagogue | TIER 1 · Clinical | — | — | — | → |
| 190 | Tesamorelin + Ipamorelin (Blend) | Two-component vendor blend — tesamorelin (long-acting GHRH analog) plus ipamorelin (selective GHS-R1a agonist hexapeptide) | Blend, GH-stack | SPECULATIVE | — | — | — | → |
| 191 | Tesofensine | Triple monoamine reuptake inhibitor (noradrenaline, dopamine, serotonin) | Metabolic | TIER 2 · Translational | — | — | — | → |
| 192 | Testagen | Khavinson-tradition tetrapeptide (Lys-Glu-Asp-Gly); proposed thymus / immune bioregulator | Longevity, Immune | SPECULATIVE | — | — | — | → |
| 193 | Tetrahydrocurcumin-Peptide | Tetrahydrocurcumin-peptide hybrid conjugate (cosmetic) | Cosmetic | SPECULATIVE | — | — | — | → |
| 194 | Tetrapeptide-21 | Synthetic tetrapeptide; INCI 'Tetrapeptide-21'; photoaging-focused cosmetic peptide | Cosmetic | SPECULATIVE | — | — | — | → |
| 195 | Thymalin | Fractionated peptide complex (multiple low-MW thymic peptides; not a defined single molecule) | Immune | TIER 3 · Preclinical | — | — | — | → |
| 196 | Thymogen | Synthetic dipeptide — L-glutamyl-L-tryptophan | Immune | TIER 3 · Preclinical | — | — | — | → |
| 197 | Thymosin Alpha-1 | 28-amino-acid peptide derived from prothymosin alpha | Healing | TIER 2 · Translational | — | — | — | → |
| 198 | Thymosin Beta-4 (TB-4) | Endogenous 43-residue actin-sequestering peptide; expressed by gene TMSB4X | Healing | TIER 2 · Translational | — | — | — | → |
| 199 | Thymulin | 9-amino-acid thymic peptide; biologically active only when bound to zinc | Healing | TIER 3 · Preclinical | — | — | — | → |
| 200 | Tirzepatide | Dual GIP / GLP-1 receptor agonist | Metabolic | TIER 1 · Clinical | — | — | — | → |
| 201 | Tuftsin | Endogenous tetrapeptide — produced by leukokininase cleavage of IgG Fc; synthesised commercially | Immune | TIER 3 · Preclinical | — | — | — | → |
| 202 | Urolithin A | Gut microbial metabolite of ellagitannins; mitophagy inducer (small molecule) | Longevity | TIER 2 · Translational | — | — | — | → |
| 203 | Vasoactive Intestinal Peptide (VIP) | Vasoactive Intestinal Peptide; 28-residue secretin-family peptide; VPAC1/VPAC2 receptor agonist | Cognitive | TIER 3 · Preclinical | — | — | — | → |
| 204 | VEGF (Vascular Endothelial Growth Factor, research) | Endogenous secreted glycoprotein growth factor; multiple isoforms (VEGF121, VEGF165, VEGF189, VEGF206 from alternative splicing) | Healing | TIER 3 · Preclinical | — | — | — | → |
| 205 | Ventfort | Khavinson-tradition vascular bioregulator (KED-class variant) | Longevity | SPECULATIVE | — | — | — | → |
| 206 | Vesugen | Khavinson-tradition tripeptide (Lys-Glu-Asp); proposed vascular endothelium bioregulator | Longevity | SPECULATIVE | — | — | — | → |
| 207 | Vilon | Khavinson-tradition dipeptide (Lys-Glu); proposed thymus / immunomodulating bioregulator | Longevity, Immune | SPECULATIVE | — | — | — | → |
| 208 | Zhenagen | Khavinson-tradition testicular / reproductive bioregulator | Longevity | SPECULATIVE | — | — | — | → |
| 209 | α-MSH (Alpha Melanocyte-Stimulating Hormone) | Endogenous tridecapeptide derived from POMC processing; native melanocortin receptor agonist | Sexual / hormonal, Cosmetic | TIER 3 · Preclinical | — | — | — | → |
◉ Pass % / N columns populate as our blind-purchase assay program brings samples through the lab queue. Until then, the compound list is organized by evidence tier and category only.